Creative Medical Technology Holdings Files Provisional Patent on Novel Type 1 Diabetes Immunotherapy Using Exosomes from MyeloCelz™ Platform
PHOENIX, Oct. 1, 2021 /PRNewswire/ — Creative Medical Technology Holdings Inc. (OTC – CELZ) announced today filing a new patent application covering nanoparticles called “exosomes” secreted by cells of its MyeloCelz™ platform and their use in the treatment of type 1 diabetes. The patent…
Comments Off on Creative Medical Technology Holdings Files Provisional Patent on Novel Type 1 Diabetes Immunotherapy Using Exosomes from MyeloCelz™ Platform